Research Indicates: Bioboosti Technology Positively Benefits Vascular Function and Blood Pressure

A randomized double-blind trial from the Mayo Clinic, involving 26 patients, divided into a Bioboosti treatment group (n=15) and a control group (n=11), aimed to investigate whether the use of Bioboosti for 12 weeks could improve endothelial vascular function, lower blood pressure, and increase nitric oxide (NO) levels in hypertensive patients.

Research Background:

Hypertension is the leading cardiovascular disease globally and in China. As a common and chronic disease, the treatment of hypertension spans a lifetime. According to surveys, the prevalence of hypertension among residents aged ≥18 in China is 27.5%. The nationwide prevalence of hypertension from 1958 to 2018 has shown an increasing trend (Figure 1)^[1]. According to the China Hypertension Survey (CHS), the awareness, treatment, and control rates of hypertension in Chinese adults aged ≥18 were 46.9%, 40.7%, and 15.3%, respectively, in 2015^[1].

Figure 1：Prevalence of hypertension in China from 1958 to 2018

However, hypertension is a modifiable risk factor, and epidemiological studies and retrospective reviews of randomized controlled trials indicate that lowering blood pressure can reduce the incidence and mortality of cardiovascular diseases.

Traditional drug interventions often lead to adverse reactions, such as elevated lipid and triglyceride levels. Drug-induced oxidative stress also increases the risk of other negative side effects and drug resistance. Moreover, endothelial dysfunction is highly correlated with cardiovascular diseases and is a common pathological process in hypertension^[2].

Research Findings:

1. The Bioboosti group showed a significant reduction in systolic blood pressure (SBP) after treatment (before vs. after treatment: 144±15 vs. 133±10 mm Hg, P<0.01), while the control group showed no change (before vs. after treatment: 143±11 vs. 145±17 mm Hg, P>0.05) (Figure 2).

Figure 2: Changes in systolic blood pressure before and after treatment in both groups

2. Diastolic blood pressure (DBP) decreased in the Bioboosti group (before vs. after treatment: 85±7 vs. 80±6 mm Hg, P<0.05), while the control group showed no change (before vs. after treatment: 83±7 vs. 85±9 mm Hg, P>0.05) (Figure 3).

Figure 3: Changes in diastolic blood pressure before and after treatment in both groups

3.The mean arterial pressure (MAP) decreased in the Bioboosti group (before vs. after treatment: 104±8 vs. 98±6 mm Hg, P<0.01), while there was no significant change in MAP in the control group (before vs. after treatment: 103±7 vs. 105±11 mm Hg, P>0.05) (Figure 4).

Figure 4: Changes in mean arterial pressure before and after treatment in both groups

Research Conclusion:

Twelve weeks of Bioboosti treatment improved endothelial vascular function and lowered blood pressure in hypertensive patients. This result suggests that PEMF treatment may be a potential non-pharmacological and non-invasive strategy for managing vascular diseases and hypertension.

In the future, larger clinical studies are needed to evaluate the clinical application of Bioboosti treatment as a targeted non-pharmacological and non-invasive option, as well as the impact of confounding factors such as obesity and age on the effectiveness of Bioboosti treatment.

Supplementary Knowledge:

Heavy Cardiovascular Disease Burden in China

In 2018, cardiovascular disease mortality ranked first among the total causes of death in both urban and rural residents in China, accounting for 46.66% in rural areas and 43.81% in urban areas. Moreover, cardiovascular disease mortality remained the highest, surpassing cancer and other diseases^[3].

A prospective cohort study of 12,952 Chinese adults aged >18 from the China Health and Nutrition Survey (CHNS) showed that the age-standardized incidence rate of hypertension increased from 40.8/1000 person-years (95% CI: 38.3-43.3) in 1993-1997 to 48.6/1000 person-years (95% CI: 46.1-51.0) in 2011-2015. Compared to the western region, residents in the eastern, central, and northeastern regions had higher incidence rates of hypertension^[4].

The prevalence of cardiovascular diseases in China is on the rise. The estimated number of people with cardiovascular diseases is 330 million, including 245 million with hypertension, 13 million with stroke, 11 million with coronary heart disease, 5 million with pulmonary heart disease, 8.9 million with heart failure, 25 million with rheumatic heart disease, 2 million with congenital heart disease, and 45.3 million with lower limb arterial disease. Calculated based on the total national population of 1.395 billion in 2018, on average, 1 in 4 people has some degree of cardiovascular and cerebrovascular disease, posing a significant challenge to the management and prevention of chronic diseases^[3].

References:

1. 张梅, 吴静, 张笑, 等 . 2018年中国成年居民高血压患病与控制状况研究. 中华流行病学杂志, 2021, 42(10): 1780-1789.

2. Stewart GM, Wheatley-Guy CM, Johnson BD, Shen WK, Kim CH. Impact of pulsed electromagnetic field therapy on vascular function and blood pressure in hypertensive individuals. J Clin Hypertens (Greenwich). 2020;22(6):1083-1089.

3. 国家心血管病中心 . 中国心血管健康与疾病报告 2021.北京: 科学出版社, 2022.

4. Luo Y, Xia F, Yu X, Li P, Huang W, Zhang W. Long-term trends and regional variations of hypertension incidence in China: a prospective cohort study from the China Health and Nutrition Survey, 1991-2015. BMJ Open. 2021;11(1):e042053.